Jubilant to work with Endo Pharmaceuticals on drug development

NOIDA, India An India-based pharmaceutical company has announced it has entered a discovery and development collaboration with a United States-based pharmaceutical company.

Jubilant Organosys, headquartered in Noida, India, announced Thursday that its Bangalore-based subsidiary, Jubilant Biosys, has entered into a discovery and development collaboration with Endo Pharmaceuticals. As part of the agreement, Jubilant and Endo would collaborate initially to develop a portfolio of targets in the area of oncology, with a focus on delivering preclinical candidates that could be selected for joint clinical development.

Endo will own any compounds developed under the collaboration and will be responsible for worldwide commercialization.

Under an initial three-year agreement, Jubilant will receive from Endo research funding and success-based development milestones and royalties on the successful commercialization of the compounds developed.

"We are excited about this opportunity with Jubilant," said Ivan Gergel, EVP research and development for Endo. "We look forward to our collaboration with the goal of bringing new therapies and healthcare solutions to patients."